Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Atherosclerosis, Cardiovascular Disease

In brief

To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of MEDI6012 in subjects with stable atherosclerosis.

Key facts

Study ID
NCT03004638
Run by
MedImmune LLC
People needed
32
Starts
2017-01-23
Expected to finish
2017-11-02
Last updated by the study team
2018-12-19

Who can join

Age: 60 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.